Journals / Turkish Journal of Urology / 2019 / Cilt: 45 - Sayı: 2

The short-term efficacy of intravesical instillation of hyaluronic acid treatment for bladder pain syndrome/interstitial cystitis

Pages
129–134
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also, Turkish versions of ICSI and ICPI forms werereliable and comprehensible.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of the study was to evaluate the short term efficacy of intravesical instillation of hyaluronic acid in patients with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).Material and methods: The study included 54 women with BPS/IC who received intravesical instillationof hyaluronic acid treatment (120 mg/50 mL) for 6 weeks.
📊
Key Findings & Data:Visual Analogue Scale (VAS), The O'Leary SantQuestionnaire (ICSI/ICPI) forms of the patients were filled by the clinician and the health technician separately before and 3 months after the treatment.
💡
Conclusion & Impact:Also, Turkish versions of ICSI and ICPI forms werereliable and comprehensible.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: The aim of the study was to evaluate the short term efficacy of intravesical instillation of hyaluronic acid in patients with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).Material and methods: The study included 54 women with BPS/IC who received intravesical instillationof hyaluronic acid treatment (120 mg/50 mL) for 6 weeks. Visual Analogue Scale (VAS), The O'Leary SantQuestionnaire (ICSI/ICPI) forms of the patients were filled by the clinician and the health technician separately before and 3 months after the treatment. Demographic characteristics of the patients were recorded,and effectiveness of the treatment was investigated according to these data.Results: Decrease in mean VAS and mean total scores of ICSI and ICPI was observed after three monthsof intravesical instillation of hyaluronic acid treatment (55%, p<0.05 and 48.5%, p<0.05 and 45.5%, p<0.05,respectively). In most of the patients, all scores of VAS, ICSI and ICPI improved (minimum: 75.9%, maximum: 94.4%). Mostly the symptoms of nocturia and pollakiuria were seen, and treated after the instillationtreatment.Conclusion: It has been observed that in the short-term follow-up of intravesical instillation of hyaluronicacid treatment, the symptoms have highly improved. Also, Turkish versions of ICSI and ICPI forms werereliable and comprehensible.

🔖

Cite This Article

AKBAY, E., ÇAYAN, S., KILINÇ, C., BOZLU, M., TEK, M., EFESOY, O. (2019). The short-term efficacy of intravesical instillation of hyaluronic acid treatment for bladder pain syndrome/interstitial cystitis. Turkish Journal of Urology, Cilt: 45 - Sayı: 2, 129–134. https://ajindex.com/articles/379737

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal. Eur Urol 2008;53:60-7. [CrossRef] Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T, et al. Bladder Pain Syndrome International Consultation on Incontinence. Neurourol Urodyn 2010;29:191-8. [CrossRef] Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic Acid: An Effective Alternative Treatment of Interstitial Cystitis, Recurrent Urinary Tract Infections, and Hemorrhagic Cystitis? Eur Urol 2007;51:1534-41. Erickson DR. Urine markers of interstitial cystitis. Urology 2001;57(Suppl 6A):15-21.
  2. Byrne DS, Sedor JF, Estojak J, Fitzpatrick KJ, Chiura AN, Mulholland SG. The urinary glycoprotein GP51 as a clinical marker for interstitial cystitis. J Urol 1999;161:1786-90. [CrossRef] Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes and Kidney Diseases workshop on interstitial cystitis. J Urol 1988;140:203-6. Hurst RE. Structure, function and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 1994;12:3-10. [CrossRef] Jost SP, Gosling JA, Dixon JS. The morphology of normal human bladder urothelium. J Anat 1989;167:103-15.
  3. Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol 2005;39:143-7. [CrossRef] Gupta SK, Pidcock L, Parr NJ. The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU Int 2005;96:1063-6. [CrossRef] Parsons CL, Stein PC, Bidair M, Lebow D. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn 1994;13:515-20. [CrossRef] Moldwin RM, Sant GR. Interstitial cystitis: a pathophysiology and treatment update. Clin Obstet Gynecol 2002;45:259-72. [CrossRef] Nordling J, Jorgensen S, Kallestrup E. Cystistat for the treatment of interstitial cystitis: a 3-year follow-up study. Urology 2001;57(6 suppl 1):123. Lokeshwar VB, Selzer MG, Unwala DJ, Estrella V, Gomez MF, Golshani R, et al. Uronate peaks and urinary hyaluronic acid levels correlate with interstitial cystitis severity. J Urol 2006;176:1001-7. [CrossRef] Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 1990;143:139-42. [CrossRef] O'Leary MP, San